Should Your Portfolio Say Hello to Halozyme Therapeutics Inc.? | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 29 August, 2015 by The TZ Newswire Staff

Should Your Portfolio Say Hello to Halozyme Therapeutics Inc.?

This small-cap biotech has been crushing the markets for years. Does it deserve a place in your portfolio?

See also
- Next Article Late ‘Simpsons’ creator’s art set for auction
- Previous Article Marketplace Lending News Roundup – August 29, 2015
Editorial Calender

August 2015

M T W T F S S

1 2

3 4 5 6 7 8 9

10 11 12 13 14 15 16

17 18 19 20 21 22 23

24 25 26 27 28 29 30

31

« Jul Sep »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar